



HAL
open science

Porphyrin-xylan-coated silica nanoparticles for anticancer photodynamic therapy

Soukaina Bouramtane, Ludovic Bretin, Aline Pinon, David Leger, Bertrand Liagre, Laurence Richard, Frédérique Brégier, Vincent Sol, Vincent Chaleix

► **To cite this version:**

Soukaina Bouramtane, Ludovic Bretin, Aline Pinon, David Leger, Bertrand Liagre, et al.. Porphyrin-xylan-coated silica nanoparticles for anticancer photodynamic therapy. *Carbohydrate Polymers*, 2019, 213, pp.168-175. 10.1016/j.carbpol.2019.02.070 . hal-02490804

HAL Id: hal-02490804

<https://hal.science/hal-02490804>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Porphyrin-xylan-coated silica nanoparticles for anticancer photodynamic therapy**

2 Soukaina Bouramtane^a, Ludovic Bretin^b, Aline Pinon^b, David Leger^b, Bertrand Liagre^b,
3 Laurence Richard^c, Frédérique Brégier^a, Vincent Sol^a, Vincent Chaleix^{a,*}

4 ^a Université de Limoges, Laboratoire PEIRENE, EA 7500, Faculté des Sciences et
5 Techniques, 123 Avenue Albert Thomas, 87060 Limoges, France.

6 ^b Université de Limoges, Laboratoire PEIRENE EA 7500, Faculté de Pharmacie, – 2, rue du
7 Docteur Marcland, 87025 Limoges, France.

8 ^c Centre Hospitalier Universitaire de Limoges, Service d'Anatomie Pathologique – 2, avenue
9 Martin Luther King 87042 Limoges cedex, France.

10 * Corresponding author. Tel.: +33 05 55 45 75 67; Fax: +33 05 55 45 72 02. E-mail address:
11 vincent.chaleix@unilim.fr (V. Chaleix).

12 **Highlights**

- 13 • Xylan-porphyrin-coated silica nanoparticles (**PX SNPs**) have been **synthesized**.
- 14 • Valorization of hemicellulose as **a** drug carrier for photodynamic therapy.
- 15 • Formed nanoparticles show high anticancer activity against colorectal cancer cell
16 lines.

17 **Abstract**

18 Porphyrins are widely used in anticancer photodynamic therapy (PDT). However, low
19 physiological solubility and lack of selectivity towards cancer cells are the main limitations of
20 their clinical use. Nanoparticles are being intensively explored as photosensitizer carriers for
21 PDT to overcome these limitations. The aims of this work are to synthesize core-shell hybrid
22 nanoparticles formed by a silica core and xylan carrying a 5-(4-hydroxyphenyl)-10,15,20-
23 triphenylporphyrin (TPPOH) shell, and evaluate their anticancer activity. To afford drug-
24 controlled incorporation and enhance blood circulation, TPPOH was covalently linked to
25 xylan. Different xylans with degrees of substitution in TPPOH ranging from 0.034 to 1.11,
26 were obtained and characterized. Then, the xylan-TPPOH conjugate (PX) was used to coat
27 the silica nanoparticles (PX SNPs). The obtained nano-objects were characterized and their
28 therapeutic potential for photodynamic therapy evaluated against colorectal cancer cell lines.

29 *In vitro* analysis showed that PX SNPs were 40-fold and 10-fold more effective against
30 HCT116 cells and HT-29 cells respectively compared to free TPPOH.

31 **Keywords** : xylan; polysaccharides; silica nanoparticles; photodynamic therapy; colorectal
32 cancer.

33

34 1. Introduction

35 Being the second leading cause of death in the world, after cardiovascular pathologies, cancer
36 is the most dreaded disease of our time (Nagai & Kim, 2017). It consists of the anarchic
37 proliferation of abnormal cells which escape from normal control mechanisms. Several
38 options are available for treating cancer; the most classic are surgery, chemotherapy and
39 radiotherapy (Saini, Chouhan, Bagri, & Bajpai, 2012). These treatments are invasive and lack
40 selectivity toward tumor cells. To better target cancer cells and minimize adverse effects, new
41 or complementary treatments have emerged over the past few years.

42 Photodynamic therapy (PDT) is an alternative and non-invasive cancer treatment requiring the
43 simultaneous presence of three elements: a photosensitive molecule, a light source and
44 molecular oxygen (Kwiatkowski et al., 2018). PDT usually involves intravenous
45 administration of a photosensitizer (PS) and subsequent specific-wavelength irradiation of the
46 tumor tissue. When irradiated, the PS passes from the ground state to the excited singlet state.
47 The excited photosensitizer is very unstable and loses its excess energy by, either non-
48 radiative (heat emission) or radiative (fluorescence emission) pathways. Another process can
49 occur, namely intersystem crossing, to form a more stable excited triplet state with parallel
50 spins. In this case, return to the ground state, theoretically forbidden transition, is very slow.
51 PS can be deactivated by phosphorescence or by reacting with its environment according to
52 two types of mechanisms. The Type I mechanism involves electron transfer from
53 photosensitizer to biological substrates to form radicals and radical ions which, after
54 interaction with oxygen, provide reactive oxygen species (ROS) such as the superoxide
55 radical anion ($O_2^{\cdot-}$). A Type II photochemical process consists of a triplet-triplet energy
56 transfer from PS to molecular oxygen in its ground state (triplet state). This energy transfer
57 leads to the formation of singlet oxygen 1O_2 and thus regenerates the ground-state
58 photosensitizer. All these species are highly reactive and are very powerful oxidants that can
59 damage cancer cells and lead to their death (Bonnett, 1995; Henderson & Dougherty, 1992).
60 Tetrapyrrole compounds such as porphyrins, chlorins, and bacteriochlorins are the most
61 utilized photosensitizers in PDT (Abrahamse & Hamblin, 2016; Sternberg, Dolphin, &
62 Brückner, 1998). However, these hydrophobic molecules are sparingly soluble in biological
63 fluids and they suffer from poor selectivity towards tumor cells which restricts their use in
64 clinical protocols.

65 Several approaches have been developed to improve PS bioavailability and efficacy in PDT.
66 One of the most promising is the attachment of PS to nanoparticles (NPs) (Kydd et al., 2017)

67 which not **only enhances** the solubility of hydrophobic photosensitizers but also **promotes**
68 their deposition inside tumors, **due** to so-called passive targeting. Indeed, leaky vasculature
69 and the resulting aberrant architecture of solid tumors **leads to preferential** nanoparticle
70 **accumulation** in tumors **which remain** there because of poor lymphatic drainage. This
71 phenomenon, known as Enhanced Permeability and Retention (EPR) effect, **was** first
72 described by Matsumura and Maeda (Matsumura & Maeda, 1986; Maeda & Matsumura,
73 1989; Maeda, 2001).

74 Various NPs have been used as delivery systems for water-insoluble drugs (Debele, Peng, &
75 Tsai, 2015), and **especially** silica nanoparticles (SNPs), which have been recognized as
76 promising vectors for PDT applications (Bharathiraja et al., 2017; Brezániová et al., 2018;
77 Roy et al., 2003; Yan & Kopelman, 2003; Yan et al., 2018;). In the last two decades, SNPs
78 have gained **an ever-increasing** interest for medical applications because of a large number of
79 qualities, including biocompatibility, stability, high specific surface area, ease of synthesis
80 with controllable size, shape and surface charge, along with their ease of functionalization
81 with a number of varied materials (Tamba et al., 2015).

82 A major obstacle **to controlled** drug delivery **is** the mononuclear phagocytic system (MPS)
83 which is responsible for the premature removal of drug carriers from the body through
84 opsonization (Frank & Fries, 1991; Gref et al., 1994). One solution proposed to **slow**
85 opsonization and **increase nanoparticle half-lives in the bloodstream by coating them** with
86 hydrophilic groups **via adsorption or covalent grafting** (Lemarchand, Gref, & Couvreur,
87 2004). These groups generally consist of long chain polymers such as polyethylene glycol
88 (PEG) (Mozar & Chowdhury, 2018; Peracchia et al., 1999), or polysaccharides such as
89 chitosan (Zhu et al., 2009) **and** dextran (Coombes et al., 1997; Mbakidi et al., 2013). These
90 polymers create a hydrophilic protective layer around the nanoparticles which **prevents** the
91 binding of opsonins via steric repulsion forces, thereby delaying opsonization and
92 phagocytosis (Owens & Peppas, 2006).

93 Xylan is a natural, biodegradable, and non-toxic biomaterial. It is the main hemicellulose
94 **component** of secondary cell walls constituting **approximately** 20–30% of the biomass of
95 dicotyl plants (hardwoods and herbaceous plants). In hardwood, 4-*O*-methylglucuronoxylan
96 (MGX) is the most abundant hemicellulose. Its structure consists of a **β(1-4)-D-xylopyranosyl**
97 backbone with 4-*O*-methyl-D-glucuronic acid (MeGlcA) side chains attached **at the 2 position**
98 of the xylose units (Ebringerová & Hromádková, 2005). The degree of substitution in
99 MeGlcA depends on **the** forest species and varies between 3.7 and 12 xylose units for one 4-

100 *O*-methylglucuronic acid unit in hardwoods. Xylan obtained from corn cobs has been
101 reported to exhibit antioxidant, anticoagulant, antimicrobial and antiproliferative properties.
102 Corn cob xylan has been shown to exert an antiproliferative effect against HeLa cell lines in a
103 dose-dependent manner (Melo-Silveira et al., 2012). In another study, chestnut tree MGX was
104 found to inhibit proliferation of A431 human squamous carcinoma cells, as well as migration
105 and invasion by inhibiting the expression of metalloproteinases MMP2 and MMP9, which are
106 involved in the degradation of the cell basement membrane and subsequent migration through
107 extracellular matrices (Moine et al., 2007). In drug delivery, esterification of beech wood
108 xylan via activation of the carboxylic acid with N, N-carbonyldiimidazole has been performed
109 to produce prodrugs for the controlled release of ibuprofen (Daus & Heinze, 2010). The
110 surface modification of magnetic nanoparticles (MNPs) with xylan has also been reported to
111 stabilize MNPs in biological media and been shown to improve their biocompatibility and
112 biodistribution (Ma et al., 2018).

113 The functionalization of xylan by porphyrins has never been reported in the literature. We
114 hypothesize that it should be possible to condense porphyrins on xylan by esterification and to
115 control the degree of substitution through the implementation of a well-chosen experimental
116 design. We assume that it must be possible to obtain nano-objects with high porphyrin content
117 through surface coating of SNPs with PX conjugate. We also assume that the anticancer
118 activity of these nanoparticles will be higher than that of free TPPOH.

119 In adequation with our research program on polysaccharide modifications with
120 photosensitizers for PDT applications (Drogat et al., 2012; Ringot et al., 2018), and in order to
121 develop new photosensitizer carriers for PDT applications, we prepared and characterized
122 core-shell hybrid nanoparticles based on xylan for the targeted delivery of 5-(4-
123 hydroxyphenyl)-10,15,20-triphenylporphyrin, a second-generation photosensitizer that is
124 relatively easy to synthesize and exhibits a singlet oxygen quantum yield of $\Phi\Delta=0.57$
125 (Managa et al., 2016). TPPOH was covalently linked to xylan via an esterification reaction
126 and then this conjugate was attached to SNPs through ionic bonds. The *in vitro* cytotoxicity
127 and photodynamic efficiency of these nanomaterials were determined against HCT116 and
128 HT-29 colorectal cancer cell lines.

129 2. Materials and methods

130 2.1. Materials

131 For a list of materials, see Supplementary Information (SI).

132 2.2. Analytical methods

133 FTIR analyses were performed on a Perkin Elmer FT-IR Spectrum 1000 spectrometer using
134 KBr pellets (1-2 wt%). NMR analyses were carried out on a Bruker DPX 500 NMR
135 spectrometer, operating at 500 MHz. UV-vis spectra were recorded on a double beam
136 spectrophotometer AnalytikaJena SPECORD 210, using 10 mm quartz cells. High resolution
137 electrospray ionization mass spectrometry (HR ESI-MS) was performed at the ICOA/CBM
138 platform (Orléans University) on a Bruker Q-TOF maXis mass spectrometer, coupled to an
139 Ultimate 3000 RSLC chain (Dionex). Purifications were performed with Combiflash Rf 100@
140 from Teledyne Isco. The stationary phase consisted of an 80 g silica column. The products to
141 be purified were solubilized in a minimum amount of solvent and fixed on Florisil (60-100
142 mesh, VWR). For Transmission Electron Microscopy (TEM) studies, one droplet of
143 nanoparticle suspension was lyophilized on a copper grid. Images were taken with a JEOL
144 2010 UHR instrument. Particle size distribution and zeta potential were analyzed through
145 dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern, UK). SNPs suspension
146 was diluted in absolute ethanol and analyzed at 20 °C at a scattering angle of 173°. The mean
147 diameter of SNPs was expressed as the average value of two measurements, each one
148 comprising 15 runs. Zeta potential data was collected through electrophoretic light scattering
149 at 20 °C, 150 V using this same instrument. Each zeta potential value is the average of two
150 measurements, each one comprised of 100 single runs. Red light (630-660nm, 75 J/cm²) was
151 delivered from the light source PhotoCure™ Lamp CURElight (PhotoCure ASA, Oslo,
152 Norway). Cell morphology was analyzed by an electron microscope JEOL JEM-1011
153 operated at 80 KeV (JEOL, Croissy-sur-Seine, France).

154 2.3. Porphyrin synthesis

155 2.3.1. [3-ethoxycarbonylpropyloxy] phenyl) -10,15,20-triphenylporphyrin (2)

156 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (1) was synthesized according to the Little
157 method (Little, Anton, Loach, & Ibers, 1975; Boscencu, Licsandru, Socoteanu, Oliveira, &
158 Ferreira, 2007). Compound 1 (0.2 g, 1 equiv, 0.32 mmol) was dissolved in 15 mL of DMF
159 with excess K₂CO₃ (25 equiv, 1.09 g, 7.92 mmol) and stirred for 5 min at room temperature.
160 Then 0.43 g of ethyl 4-bromobutyrate (7 equiv, 2.22 mmol) were added. The reaction was
161 carried out using microwave irradiation at 120 °C and 300 W for 7 min and monitored by
162 thin-layer chromatography (TLC). After evaporation of DMF under vacuum, the crude
163 product was dissolved in chloroform (15 mL). The organic layer was washed with water (3 ×

164 30 mL), dried (MgSO₄) and then evaporated to give, after purification by flash
165 chromatography on a silica column, (eluent: petroleum ether/CHCl₃ from 80 to 100%) a pure
166 porphyrin **2** with 91% yield. Rf= 0.44 (CHCl₃), ¹H NMR (CDCl₃, 500.15 MHz) δH, ppm : -
167 2.74 (s, 2H, NH pyrrole), 1.32 (t, 3H, J = 7.5 Hz, CH₃ ethyl), 2.27 (q, 2H, J= 6.5 Hz, Hβ -
168 CH₂-), 2.66 (t, 2H, J = 7.5 Hz, -CH₂-C=O), 4.22 (q, 2H, J= 7 Hz, CH₂ ethyl), 4.25 (t, 2H, J=
169 6 Hz, -O-CH₂-), 7.22 (d, 2H, J= 8.5 Hz, H_{3,5} aryl), 7.72 (m, 9H, H_{3,4,5} phenyl), 8.10 (d, 2H,
170 J = 8.5 Hz, H_{2,6} aryl), 8.20 (d, 6H, J= 7.5 Hz, H_{2,6} phenyl), 8.83 (s, 8H, Hβ pyrrole). ¹³C
171 NMR (CDCl₃, 500.15 MHz) δc, ppm : 14.31 (CH₃ ethyl) ; 24.87 (-CH₂-) ; 30.99 (CH₂-C=O) ;
172 60.52 (CH₂ ethyl); 67.03 (O-CH₂); 112.72 (C-3,5 aryl); 119.96-120.07 (C meso); 126.68-
173 127.67 (C phenyl); 130.88-131.13 (Cβ pyrrole); 134.54-134.59 (C-2,6 aryl); 135.59 (C-1 aryl)
174 ; 142.19-142.22(Cα pyrrole); 158.70 (C-4 aryl); 173.30 (C=O). UV-Visible : UV-Vis
175 (CHCl₃) λ max nm (ε, 10³ L.mol⁻¹.cm⁻¹) : 420 (609), 519 (21), 553 (10), 591 (6), 649 (5). MS
176 (ESI): m/z = 745.3173 [M+H]⁺.

177 2.3.2. 5-(2-[3-carboxypropyloxy] phenyl) -10,15,20-triphenylporphyrin (**3**)

178 **Compound 2** (0.3 g, 1 equiv, 0.4 mmol) was dissolved in 15 mL DMF and then 0.16 g (10
179 equiv, 4 mmol) NaOH previously dissolved in 2 mL of distilled water, was added. The
180 reaction was allowed to proceed under stirring for 2 h at 100 °C. After solvent evaporation,
181 the crude product was dissolved in chloroform (15 mL) and neutralized with 287.5 μL
182 hydrochloric acid (HCl) (37%, 12 M), washed with distilled water (3x30 mL), dried over
183 MgSO₄, and evaporated. Then, the crude product was purified by flash chromatography to
184 give **TPPOH** (compound **3**) as a purple solid (yield 96%) (eluent: CHCl₃/Ethanol from 100 to
185 90%). Rf= 0.6 (EtOH/CHCl₃ 1/9), ¹H NMR (CDCl₃+10% TFA, 500.15 MHz) δH, ppm: 2.39
186 (q, 2H, -CH₂-, J= 8Hz), 2.86 (t, 2H, CH₂-C=O, J = 6.5Hz), 2.48 (t, 2H, CH₂-O, J= 6Hz), 7.56
187 (d, 2H, H_{3,5} aryl, J= 7.7Hz), 8.02 (m, 9H, H_{3,4,5} phenyl), 8.53 (m, 8H, H_{2,6} phenyl, H_{2,6}
188 aryl), 8.7 (s, 8H, Hβ pyrrole). ¹³C NMR (CDCl₃, 500.15 MHz) δc, ppm : 24.6 (-CH₂-) ; 30.9
189 (CH₂-C=O) ; 67.1 (O-CH₂); 115.09 (C-3,5 aryl); 122.44-123.98 (C meso) ; 128.79-129.55 (C
190 phenyl) ; 130.79-133.02 (C βpyrrole) ; 139.2-138.3 (C-2,6 aryl); 140.3 (C1 aryl) ; 146.46-
191 145.17(C αpyrrole) ; 161.1 (C-4 aryl) ; 181 (C=O). UV-Vis (CHCl₃) λ max nm (ε, 10³
192 L.mol⁻¹.cm⁻¹): 420 (451), 516 (21), 553 (10), 591 (6), 647 (5). MS (ESI): m/z = 717.286
193 [M+H]⁺.

194

195

196 2.4. Synthesis of PX

197 3.4.1. Solubilization of xylan

198 Xylan (1g) was dissolved in 20 mL DMSO (60 °C) and filtered to remove the insoluble
199 fraction. To determine the concentration of this solution, 1 mL was precipitated with 3 mL
200 absolute ethanol, filtered and dried under vacuum. The mass of precipitated xylan was 44.5
201 mg, therefore the xylan solution in DMSO had a concentration of 44.5 mg/mL (absence of
202 polysaccharide in the filtrate was verified by TLC.

203 3.4.2. TPPOH grafting to xylan

204 All syntheses were carried out following the same protocol. TPPOH was added to 1
205 equivalent of N, N-carbonyldiimidazole (CDI) and stirred in DMSO at room temperature for
206 24 h. This solution was then added to a solution of 100 mg (0.76 mmol anhydroxylose unit)
207 xylan in DMSO and allowed to react under stirring. Reaction parameters are summarized in
208 Table S1 (SI). The product was precipitated out in absolute ethanol and was washed three
209 times with ethanol and three times with chloroform to remove unreacted starting material and
210 then dried under vacuum.

211 2.5. Synthesis and surface modification of SNPs

212 3 mL aqueous ammonia (28%) and 1.5 mL tetraethoxysilane (TEOS) were successively
213 added dropwise to 45 mL absolute ethanol. This solution was stirred for 4 h at 48 °C.
214 Resulting SNPs were collected by centrifugation (8000 rpm, 30 min), washed three times with
215 ethanol and then dispersed in 25 mL 96% ethanol. Then, 4 mL (3-aminopropyl)
216 triethoxysilane (APTES) was added and stirred overnight. After three cycles of
217 centrifugation/redispersion in ethanol, SNPs were obtained as a white solid and were stored in
218 25 mL of absolute ethanol.

219 2.6. Grafting of PX onto surface-modified SNPs

220 PX (10 mg) was dissolved in 20 mL distilled water. Then 100 mg SNPs in ethanol were
221 added dropwise and ultrasonicated during the addition. This mixture was then stirred for 20
222 min. The resulting PX SNPs were centrifuged and washed three times with water and absolute
223 ethanol.

224

225

226 2.7. Determination of TPPOH concentration in SNPs

227 The amount of TPPOH attached to the SNPs was determined by UV-visible assay. PX SNPs
228 were dispersed in absolute ethanol at a concentration of 10 mg/mL and diluted to 0.5 mg/mL.
229 Absorbance of this sample was measured at 418 nm, and absorbance of SNPs was subtracted.
230 The PX content of SNPs was calculated from a calibration curve constructed with different
231 concentrations of free PX in distilled water. The concentration of TPPOH in mol/L was
232 calculated according to Eq. (1):

$$C = \frac{DSxM(PX)}{M(\text{repeat unit of xylan}) + DSx(M(TPPOH) - 18)} \quad (1)$$

233 M(PX) = concentration of PX in g/L attached to SNPs, calculated from the standard
234 calibration curve

235 M (repeat unit of xylan: xyl/MeGlcA 10 :1) = 1511 g/mol

236 M (TPPOH)= 717.286 g/mol

237 2.8. In vitro experiments

238 2.8.1. Cell lines, cell culture, and PX SNPs

239 For all experiments, cells were seeded at 1.2×10^4 cells/cm² and 2.08×10^4 cells/cm² for
240 HCT116 and HT-29 cells, respectively and were grown for 24 h in culture medium prior to
241 exposure, or lack of, to TPPOH or PX SNPs at indicated concentrations. Stock solutions of
242 TPPOH (5 mg/mL) and PX SNPs 80 nm (20 mg/mL) were prepared in ethanol.

243 2.8.2. PX SNPs toxicity tests

244 PX-SNPs cytotoxicity was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
245 diphenyltetrazolium bromide (MTT) assays. Human colorectal cancer cells were seeded at
246 4×10^3 cells/well and 7×10^3 cells/well for HCT116 and HT-29 cells, respectively, in 96-well
247 culture plates and grown for 24 h in culture medium prior to exposure, or lack of, to TPPOH
248 or PX SNPs. Stock solutions of TPPOH and PX SNPs were diluted in culture medium to
249 obtain the appropriate final concentrations. The same amount of vehicle (percentage of
250 ethanol did not exceed 0.6%) was added to control cells. After 24 h, culture medium was
251 replaced by phenol red-free culture medium and cells were irradiated, or not, by red light
252 (630-660 nm, 75 J/cm²). MTT assays were done 48 h after irradiation and experiments were
253 performed in triplicate.

254 2.8.3. Transmission electron microscopy (TEM)


255 HCT116 cells (3×10^5) were seeded in 25 cm^2 tissue culture flasks and grown for 24 h in
256 culture medium prior to exposure or not to PX SNPs. After 24 h, culture medium was
257 replaced by phenol red-free culture medium and cells were irradiated, or not, by red light (75
258 J/cm^2). Then, cells were fixed in 2.5% glutaraldehyde for 30 min at room temperature and
259 washed in phosphate buffer for 15 min. They were then incubated in 1% osmium tetroxide
260 solution for 30 min at room temperature, dehydrated with increasing ethanol concentrations,
261 and embedded in epon. They were polymerized over 48 h at 60°C and ultrathin sections ($80-$
262 100 nm) were prepared. Grids were stained with uranyl acetate and lead citrate and examined
263 with TEM operated at 80 KeV .

264 2.8.4. Statistical analysis

265 Data are expressed as the arithmetic means \pm standard error of the mean (SEM) of separate
266 experiments. The statistical significance of results obtained from *in vitro* studies was
267 evaluated by the two tailed unpaired Student's t-test, with $p < 0.05$ being considered as
268 significant.

269 **3. Results and discussion**

270 Preparation of PX SNPs is summarized in Fig.1. TPPOH was conjugated with xylan via an
271 esterification reaction forming PX which was used in the surface modification of SNPs. The
272 presence of glucuronic acid groups on xylan allows the formation of ionic bonds on the
273 surface of SNPs which is made cationic by APTES.



274

275 Fig. 1. General procedure for the synthesis of PX SNPs.

276


277 3.1. Characterization of xylan

278 The xylan used in this study was characterized by the classical methods already described in
279 the literature (Kerrouche et al. 2018). It had an average polymerization degree of 208
280 calculated as the ratio of amount of total sugars to the quantity of reducing sugars. The
281 composition was characterized by colorimetric assay and contained 92.5% xylose and 7.5%
282 glucuronic acids. ^1H NMR spectrum of this xylan (Fig. S1, SI) showed the signal
283 corresponding to anomeric protons of substituted xylose units at 4.5 ppm, non-substituted
284 xylose units at 4.6 ppm and anomeric protons of uronic acid at 5.3 ppm. The degree of
285 substitution of xylan by 4-*O*-methylglucuronic acid, which was about 1/10, was calculated
286 according to Eq. (A.1, SI).

287

288 3.2. PX synthesis

289 The synthesis route of PX is summarized in Fig. 2. First, 5-(4-hydroxyphenyl)-10,15,20-
290 triphenylporphyrin (**1**) was synthesized according to the Little method and obtained with a
291 3.7% yield in agreement with the literature. It was then functionalized with ethyl 4-
292 bromobutyrate through nucleophilic substitution, activated by microwave irradiation
293 according to Chaleix et al. (2009). Product **2** was obtained with 91% yield. After
294 saponification with sodium hydroxide, porphyrin derivative **3** was obtained with 96% yield.
295 The structures of all compounds were confirmed by ^1H , ^{13}C NMR and mass spectrometry.
296 Compound **3** was then covalently attached to xylan by esterification using CDI as the
297 coupling reagent.




298

299 Fig. 2. Synthesis of PX. *i*: ethyl 4-bromobutyrate, K_2CO_3 , DMF, MW; *ii*: NaOH, DMF/Water, HCl (0.1M); *iii*:
300 Xylan, DMSO, CDI, t(h), T(°C).

301 The covalent binding between xylan and TPPOH was confirmed by FTIR. The corresponding
302 FTIR spectrum of PX is displayed in Fig. 3 (c). This compound and native xylan (Fig. 3 b),

303 shared a characteristic absorption band around 3400 cm^{-1} , which has been assigned to the
304 stretching vibrations of hydroxyl groups of xylan. There were two other bands at 2920 cm^{-1}
305 and 1441 cm^{-1} that represent the stretching and deformation vibrations of C-H bond. PX also
306 displayed new signals that correspond to the TPPOH moiety ($1245, 1178, 796, 730\text{ cm}^{-1}$) and
307 a peak at 1739 cm^{-1} that corresponds to the carbonyl functionality of TPPOH. The $^1\text{H NMR}$
308 spectrum of modified xylan (Fig. 4) identified protons of the xylose units between 3 and 5.5
309 ppm, and the peripheral protons of TPPOH between 7 and 9 ppm. The broad singlet at -2.9
310 ppm was assigned to the NH internal protons of the porphyrin pyrrole units, which is in
311 agreement with classical $^1\text{H NMR}$ spectra of porphyrins.




312

313 Fig. 3. FTIR Spectra of TPPOH (a), native xylan (b), and PX (c).

314

315



316

317 Fig. 4. ^1H NMR spectra of native xylan (a), and PX (b) in DMSO (DS=0.2).

318

3.3. Experimental design

319


Esterification reactions are mainly influenced by reaction time, temperature and molar ratio of reagents. The efficiency of **this** esterification reaction was expressed by the degree of substitution and weight yield. In order to **determine** optimal conditions **and study** the **variations** of the degree of substitution (DS) and weight yield **as a function** of temperature, reaction time and **TPPOH** equivalents, **an experimental design was built**. The choice of factors and their modes are listed in Table S2 (SI). For 3 factors, 27 experiments **needed to be** performed to explore the **entire** experimental field. In order to reduce the number of tests **and still keep** the possibility of studying all factors, **a latin square design of experiments was constructed**. **In this way** only nine experiments were performed, applying the experimental conditions summarized in Table S1 (SI). For the nine samples, DS and weight yield were measured and the obtained values **listed** in Table S3 (SI).

330

331 DS was expressed as the number of TPPOH molecules per xylan repeat unit. The DS value
 332 was calculated from ¹H NMR data according to Eq. (2):

$$DS = \frac{H(TPPOH)/27}{H1(xylan)/10} \quad (2)$$


333 Where H(TPPOH) is the integral area of TPPOH protons at δ 7.26-9.12 ppm, and H1(xylan)
 334 is the integral area of anomeric protons of substituted and non-substituted xylose units at δ
 335 4.12-4.7 ppm. To determine the effect of each factor on the degree of substitution in TPPOH,
 336 independently from the other factors, an average DS for each modality was calculated. Then,
 337 variation of the mean DS according to the modalities of the three factors was examined. As
 338 shown in Fig. 5, at all temperature and reaction times, an increase in TPPOH equivalents led
 339 to an increase in DS. Reaction time had no significant effect on DS beyond 24 hours.
 340 Furthermore, temperature increases over 50°C resulted in a drop in DS.



341

342 Fig. 5. Average effect of temperature, reaction time and TPPOH equivalent on DS.

343 The influence of these factors on weight gain was also studied. The variation of the average
 344 weight yield according to each factor is illustrated in Fig. 6.



345

346 Fig. 6. Effects of temperature, reaction time and TPPOH equivalent on weight yield.

347 Increases in the amount of TPPOH led to increased weight yields, and a slight increase in
 348 weight was observed as a function of reaction time beyond 24 h. Temperatures above 50 °C
 349 induced a slight decrease in DS.


350 Different degrees of substitution ranging from 0.034 to 1.11 were obtained. Among the nine
 351 samples we chose S9 sample showed the highest DS in TPPOH (DS = 0.2) while remaining
 352 water soluble.

353 3.4. Synthesis of core-shell hybrid nanoparticles

354 3.4.1. Synthesis of SNPs

355 To prepare core-shell hybrid nanoparticles, SNPs were first synthesized by the sol-gel process
 356 based on the modified Stöber method (Stöber, Fink, & Bohn, 1968), using TEOS as starting
 357 material. Monodispersed colloidal silica particles were produced by hydrolysis and
 358 polycondensation of TEOS, in the presence of ammonia as a catalyst in alcoholic media.

359 TEM images showed spherical shape nanoparticles with an average diameter of 80 nm (Fig. 7
 360 A). Dynamic light scattering (DLS) confirmed TEM results and the hydrodynamic diameter
 361 was measured as 78.43 ± 19.92 nm with a 0.062 polydispersity index (PDI). Zeta potential
 362 measurements showed the presence of negative charges on the surface of nanoparticles due to
 363 hydroxyl groups, as reported in Table S4 (SI).



364

365

Fig. 7. TEM images of (A) SNPs, (B) SNPs-APTES, and (C) PX SNPs.

366

367

368

369

370

371

These nanoparticles were then functionalized by APTES according to the same sol-gel mechanism. The surface modification of SNPs was confirmed by zeta potential measurements. Results showed the presence of positive charges on the surface of nanoparticles due to the ammonium groups supplied by APTES. TEM measurements (Fig. 7 B) showed no significant changes in size compared to starting nanoparticles. DLS size distribution and zeta potential curves are reported in Fig. S2 (SI).

372 3.4.2. Functionalization of SNPs with PX

373 Beech xylan exhibits a specific xylose to methyl-glucuronic acid ratio estimated to be 10:1.
374 Furthermore, it **has been** reported that the pKa value for the most common types of uronic
375 acids found in xylan is 3.2–3.7 (Österberg, Laine, Stenius, Kumpulainen, & Claesson, 2001).
376 Therefore, in ultra-pure water (pH~6.5) glucuronic acid groups will allow the attachment of
377 xylan to the **SNPs** through ionic bonds with the previously introduced ammonium groups. In
378 practice, a suspension of **SNPs** in ethanol was added dropwise to a solution of PX in water.
379 The resulted PX SNPs were collected by centrifugation and the unattached polymer was
380 removed by washing several times with water. Color change of SNPs after coating with PX
381 can be seen in Fig. S3 (**SI**). TEM measurements (Fig. 7 C) showed no significant changes in
382 size and shape of SNPs.

383 The functionalization of SNPs with PX was confirmed by UV-visible analysis (Fig. S4, **SI**).
384 The amount of PX bound to the nanoparticles was evaluated **using a standard** calibration
385 curve obtained from different concentrations of free PX diluted in water. We used a PX
386 characterized **by a 0.2 degree of substitution which associated 9.77×10^{-6} mol TPPOH per gram**
387 of silica (Table S5, **SI**).

388 3.5. In vitro cytotoxicity of PX SNPs


389 **Phototoxicity** of TPPOH and PX SNPs **was studied in** two human colorectal cancer cell lines
390 with different grade: HCT116 (grade I) and HT-29 (grade II). Toxicity was determined 48 h
391 post-irradiation **by** MTT assay. **Both** compounds proved **to be** non toxic against cells kept in
392 the dark (data not shown). When the PS **was irradiated** by 630-660 nm **red light, strong**
393 **toxicity was exerted** on the cell lines. IC₅₀ values were determined (Table 1) in order to
394 compare PS effects. We observed that TPPOH was less effective against the two human
395 colorectal cancer cell lines. In fact, compared to TPPOH, PX SNPs **were** 40-fold **and 10-fold**
396 more effective against HCT116 cells against HT-29 cells **respectively**, the former being
397 significantly less resistant than the latter. These compounds were used at their respective IC₅₀
398 values in the next experiments.

399 Table 1. *In vitro* phototoxicity of PX SNPs in human colorectal cancer cells.

| | IC ₅₀ (nM) | |
|----------------------|-----------------------|-------------|
| | HCT116 | HT-29 |
| TPPOH free | 2943 ± 102 | 5959 ± 430 |
| PX SNPs ^a | 72.6 ± 2.8 | 550.2 ± 7.5 |

400 ^a IC₅₀ nM concentrations are directly corresponding to the amount of TPPOH on the SNPs.

401 The morphology of HCT116 cells was characterized by TEM analysis (Fig. 8). After 630-660
 402 nm irradiation, untreated cells exhibited abundant microvilli, the sign of normal morphology.
 403 Cells treated with PX SNPs kept in the dark showed NPs uptake without morphological
 404 changes. However, cells treated with PX SNPs and then irradiated showed complete
 405 breakdown of intracellular structures. These cells exhibited morphological features such as
 406 cell membrane shrinkage, nuclear condensation and formation of phagocytic vesicles or
 407 apoptotic bodies, hallmark events of apoptosis (Elmore, 2007).



408

409 Fig. 8. TEM analysis of HCT116 cells (a) control cell (irradiated) (b) PX SNPs (dark), (c) PX SNPs (irradiated);
 410 White arrows indicate SNPs inside cytoplasm.

411

412 4. Conclusion

413 Xylan was successfully modified with TPPOH and nine samples were obtained with DS
 414 ranging from 0.034 to 1.11. The sample showing the highest DS in TPPOH while remaining
 415 soluble in water was used to coat SNPs through ionic bonds. The color change of SNPs even
 416 after several washes with distilled water indicated efficient coating of SNPs with PX. Thus,
 417 xylan proved effective for the surface incorporation of active molecules in controlled
 418 quantities. At the cellular level, the conjugation of TPPOH to SNPs significantly enhanced its
 419 solubility and consequently its uptake by cancer cells. Therefore, the cell-killing efficiency

420 was higher with PX SNPs compared to free TPPOH. Furthermore, cell death occurred by
421 apoptosis as confirmed by TEM morphological characterization.

422

423 **Acknowledgments**

424 The authors are indebted to Dr. Michel Guilloton, **Dáire Gibbons**, and **Jeanne Moreau** for help
425 in manuscript editing, and they gratefully acknowledge Pierre Carles (Carmalim Platform-
426 IRCER– University of Limoges) for TEM images and Dr. Yves Champavier for NMR
427 analysis.

428 **References**

429 Abrahamse, H., & Hamblin, M.R. (2016). New photosensitizers for photodynamic therapy.
430 *Biochemical Journal*, 473, 347–364.

431 Bonnett, R. (1995). Photosensitizers of the porphyrin and phthalocyanine series for
432 photodynamic therapy. *Chemical Society Reviews*, 24, 19–33.

433 Boscencu, R., Licsandru, D., Socoteanu, R., Oliveira, A.S., Ferreira, L.F.V. (2007). Synthesis
434 and spectral characterization of some unsymmetrically-substituted mesoporphyrinic
435 compounds. *Revista de Chimie*, 58, 498–501.

436 Bharathiraja, S., Moorthy, M.S., Manivasagan, P., Seo, H., Lee, K.D., & Oh, J. (2017).
437 Chlorin e6 conjugated silica nanoparticles for targeted and effective photodynamic therapy.
438 *Photodiagnosis and Photodynamic Therapy*, 19, 212–220.

439 Brezániová, I., Záruba, K., Králová, J., Sinica, A., Adámková, H., Ulbrich, P., Poučková, P.,
440 Hrubý, M., Štěpánek, P., & Král, V. (2018). Silica-based nanoparticles are efficient delivery
441 systems for temoporfin. *Photodiagnosis and Photodynamic Therapy*, 21, 275–284.

442 Coombes, A.G.A., Tasker, S., Lindblad, M., Holmgren, J., Hoste, K., Toncheva, V., Schacht,
443 E., Davies, M.C., Illum, L., & Davis, S.S. (1997). Biodegradable polymeric microparticles for
444 drug delivery and vaccine formulation: the surface attachment of hydrophilic species using
445 the concept of poly (ethylene glycol) anchoring segments. *Biomaterials*, 18, 1153–1161.

446 Chaleix, V., Couleaud, P., Sol, V., Zerrouki, R., Alves, S., & Krausz, P. (2009). Microwave-
447 assisted expeditious O-alkylation of *meso*-hydroxyphenylporphyrins. *Journal of Porphyrins
448 and Phthalocyanines*, 13, 888–892.

449 Daus, S., & Heinze, T. (2010). Xylan-based nanoparticles: prodrugs for ibuprofen release.
450 *Macromolecular Bioscience*, 10, 211–220.

451 Drogat, N., Granet, R., Le Morvan, C., Bégau-Grimaud, G., Krausz, P., Sol, V. (2012).
452 Chlorin-PEI-labeled cellulose nanocrystals: synthesis, characterization and potential
453 application in PDT. *Bioorganic & Medicinal Chemistry Letters*, 22, 3648–3652.

454 Debele, T.A., Peng, S., & Tsai, H.C. (2015). Drug carrier for photodynamic cancer therapy.
455 *International Journal of Molecular Sciences*, 16, 22094–22136.

456 Ebringerová, A., Hromádková, Z., & Heinz, T. (2005). Hemicellulose. *Advances in Polymer*
457 *Science*, 186, 1–67.

458 Elmore, S. (2007). Apoptosis: a review of programmed cell death. *Toxicologic Pathology*, 35,
459 495–516.

460 Frank, M.M., & Fries, L.F. (1991). The role of complement in inflammation and
461 phagocytosis. *Immunology Today*, 12, 322–326.

462 Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V., & Langer, R.
463 (1994). Biodegradable long-circulating polymeric nanospheres. *Science*, 263, 1600–1603.

464 Henderson, B.W., & Dougherty, T.J. (1992). How does photodynamic therapy work?
465 *Photochemistry and photobiology*, 55, 145–157.

466 Kerrouche, Dj., Sadoun, T., Stoclet, G., Sol, V., Gloaguen, V., Chaleix, V. (2018) Synthesis
467 and characterization of xylan-graft-poly(L-lactide). *International Journal of Polymer Analysis*
468 *and Characterization*, 23, 193-206

469 Kydd, J., Jadia, R., Velpurisiva, P., Gad, A., Paliwal, S., & Rai, P. (2017). Targeting
470 strategies for the combination treatment of cancer using drug delivery systems.
471 *Pharmaceutics*, 9, 46.

472 Kwiatkowski, S., Knap, B., Przystupski, D., Saczko, J., Kędzierska, E., Knap-Czop, K.,
473 Kotlińska, J., Michel, O., Kotowski, K., & Kulbacka, J. (2018). Photodynamic therapy–
474 mechanisms, photosensitizers and combinations. *Biomedicine & Pharmacotherapy*, 106,
475 1098–1107.

476 Little, R.G., Anton, J.A., Loach, P.A., & Ibers, J.A. (1975). The synthesis of some substituted
477 tetraarylporphyrins. *Journal of Heterocyclic Chemistry*, 12, 343–349.

478 Lemarchand, C., Gref, R., & Couvreur, P. (2004). Polysaccharide-decorated nanoparticles.
479 *European Journal of Pharmaceutics and Biopharmaceutics*, 58, 327–341.

480 Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in
481 cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor
482 agent smancs. *Cancer Research*, 46, 6387–6392.

483 Maeda, H., & Matsumura, Y. (1989). Tumoritropic and lymphotropic principles of
484 macromolecular drugs. *Critical Reviews in Therapeutic Drug Carrier Systems*, 6, 193–210.

485 Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor
486 vasculature: the key role of tumor-selective macromolecular drug targeting. *Advances in*
487 *Enzyme Regulation*, 41, 189–207.

488 Moine, C., Krausz, P., Chaleix, V., Sainte-Catherine, O., Kraemer, M., & Gloaguen, V.
489 (2007). Structural characterization and cytotoxic properties of a 4-O-methylglucuronoxylan
490 from castanea sativa. *Journal of Natural Products*, 70, 60–66.

491 Melo-Silveira, R.F., Fidelis, G.P., Pereira Costa, M.S.S., Silva Telles, C.B., Dantas-Santos,
492 N., de Oliveira Elias, S., Bley Ribeiro, V., Barth, A. L., Macedo, A. J., Lisboa Leite, E., &
493 Oliveira Rocha, H. A. (2012). *In vitro* antioxidant, anticoagulant and antimicrobial activity
494 and in inhibition of cancer cell proliferation by xylan extracted from corn cobs. *International*
495 *Journal of Molecular Sciences*, 13, 409–426.

496 Managa, M., Mack, J., Gonzalez-Lucasb, D., Remiro-Buenamañana, S., Tshangana, C.,
497 Cammidge, A.N., Nyokong, T. (2016). Photophysical properties of
498 tetraphenylporphyrin-subphthalocyanine conjugates. *Journal of Porphyrins and*
499 *Phthalocyanines*, 20, 1–20.

500 Mbakidi, J-P., Herke, K., Alvès, S., Chaleix, V., Granet, R., Krausz, P., Leroy-Lhez, S.,
501 Ouk, T-S., Sol, V. (2013). Synthesis and photobiocidal properties of cationic porphyrin-
502 grafted paper. *Carbohydrate Polymers*, 99, 333-338.

503 Ma, J., Li, D., Zhong, L., Du, F., Tan, J., Yang, J., & Peng, X. (2018). Synthesis and
504 characterization of biofunctional quaternized xylan-Fe₂O₃ core/shell nanocomposites and
505 modification with polylysine and folic acid. *Carbohydrate Polymers*, 199, 382–389.

506 Mozar, F.S., & Chowdhury, E.H. (2018). PEGylation of carbonate apatite nanoparticles
507 prevents opsonin binding and enhances tumor accumulation of gemcitabine. *Journal of*
508 *Pharmaceutical Sciences*, 107, 2497–2508.

509 Nagai, H., & Kim, Y.H. (2017). Cancer prevention from the perspective of global cancer
510 burden patterns. *Journal of Thoracic Disease*, 9, 448–451.

511 Österberg, M., Laine, J., Stenius, P., Kumpulainen, A., & Claesson, P.M. (2001). Forces
512 between xylan-coated surfaces: effect of polymer charge density and background electrolyte.
513 *Journal of Colloid and Interface Science*, 242, 59–66.

514 Owens D.E. 3rd, & Peppas N.A. (2005). Opsonization, biodistribution, and pharmacokinetics
515 of polymeric nanoparticles. *International Journal of Pharmaceutics*, 307, 93–102.

516 Peracchia, M.T., Fattal, E., Desmaële, D., Besnard, M., Noël, J.P., Gomis, J.M., Appel, M.,
517 d'Angelo, J., & Couvreur, P. (1999). Stealth PEGylated polycyanoacrylate nanoparticles for
518 intravenous administration and splenic targeting. *Journal of Controlled Release*, 60, 121–128.

519 Roy, I., Ohulchanskyy, T.Y., Pudavar, H.E., Bergey, E.J., Oseroff, A.R., Morgan, J.,
520 Dougherty, T.J., & Prasad, P.N. (2003). Ceramic-based nanoparticles entrapping water-
521 insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic
522 therapy. *Journal of the American Chemical Society*, 125, 7860–7865.

523 Ringot, C., Saad, N., Brégier, F., Bressollier, P., Poli, E., Chaleix, V., Ouk, T.S., Sol, V.
524 (2018). Antibacterial activity of a photosensitive hybrid cellulose fabric. *Photochemical and*
525 *Photobiological Sciences*, 17, 1780–1786.

526 Stöber, W., Fink, A., & Bohn, E. (1968). Controlled growth of monodisperse silica spheres in
527 the micron size range. *Journal of Colloid and Interface Science*, 26, 62–69.

528 Sternberg, E.D., Dolphin, D., & Brückner, C. (1998). Porphyrin-based photosensitizers for
529 use in photodynamic therapy. *Tetrahedron*, 54, 4151–4202.

530 Saini, R.K., Chouhan, R., Bagri L.P. & Bajpai, A.K. (2012). Strategies of targeting tumors
531 and cancers, *Journal of Cancer Research Updates*, 1, 129–152.

532 Tamba, B.I., Dondas, A., Leon, M., Neagu, A.N., Dodi, G., Stefanescu, C., & Tijani, A.
533 (2015). Silica nanoparticles: preparation, characterization and in vitro/in vivo biodistribution
534 studies. *European Journal of Pharmaceutical Sciences*, 71, 46–55.

535 Yan, F., & Kopelman, R. (2003). The embedding of meta-tetra(hydroxyphenyl)-chlorin into
536 silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production
537 and pH-dependent optical properties. *Photochemistry and Photobiology*, 78, 587–591.

- 538 Yan, T., Cheng, J., Liu, Z., Cheng, F., Wei, X., & He, J. (2017). pH-sensitive mesoporous
539 silica nanoparticles for chemo-photodynamic combination therapy. *Colloids and Surfaces B.*
540 *Biointerfaces*, 161, 442–448.
- 541 Zhu, A., Yuan, L., Jin, W., Dai, S., Wang, Q., Xue, Z., & Qin, A. (2009). Polysaccharide
542 surface modified Fe₃O₄ nanoparticles for camptothecin loading and release. *Acta*
543 *Biomaterialia*, 5, 1489–1498.